The PIP breast implants — 300,000 Women Filled With Secret Industrial Silicone
Summary
When France's medical-safety agency AFSSAPS suspended Poly Implant Prothèse's silicone breast implants and forced the company into liquidation in March 2010, the gap between what founder Jean-Claude Mas had sold and what he had actually manufactured had been hidden for nearly a decade: since roughly 2001, PIP had quietly filled most of its implants with an in-house industrial-grade silicone — a gel built from chemicals such as Baysilone, Silopren, and Rhodorsil intended for fuel additives and rubber, not the medical-grade material on its certificates. The substitution cut the gel cost by close to 90 percent, from on the order of €35 per litre to roughly €5. The legend PIP traded on — a cut-price, CE-marked, third-largest implant maker in the world — was, for most of the prostheses it shipped, a fraud the company kept two sets of records to conceal.
The harm was mechanical and then systemic. The unapproved gel sat in shells that ruptured and leaked at rates independent reviews placed between 5 and 11 percent, against under 1 percent for approved implants — an elevation on the order of fivefold. When the shells failed, the industrial filler bled into surrounding tissue, provoking inflammation, lymph-node reactions, and repeat surgery. By the end of 2011, regulators were tracking roughly twenty cancer cases among PIP recipients and one death attributed to anaplastic large-cell lymphoma, though no causal link to the silicone was ever established. An estimated 300,000 women in some 65 countries carried the devices, many fitted for breast reconstruction after cancer.
Recall did not mean retrieval. Pulling the product and liquidating the maker left hundreds of thousands of devices inside bodies; on 23 December 2011 the French government went further than most and recommended that about 30,000 French women have the implants removed as a precaution. Criminal justice followed the bankruptcy: a Marseille court convicted Mas of aggravated fraud on 10 December 2013, sentencing him to four years in prison and a €75,000 fine and barring him from medicine and company management — upheld on appeal at Aix-en-Provence in May 2016. The deeper failure was the certification chain: notified body TÜV Rheinland had inspected PIP repeatedly between the late 1990s and 2010 without catching the swap, and in May 2021 the Paris Court of Appeal found it negligent and liable to victims. The scandal became the proximate fuel for the European Union's 2017 Medical Device Regulation, the law written to close the door PIP had walked through.
Timeline
The Butcher's Margin
PIP's competitive edge was price, and price was engineered through substitution. From around 2001 the company filled the bulk of its implants not with the medical-grade silicone its CE certificates described but with an industrial gel mixed in-house from compounds such as Baysilone, Silopren, and Rhodorsil — materials tied to fuel additives and rubber, reduced in the press to "mattress-grade" filler. The economics were stark: the unapproved gel cost on the order of €5 per litre against roughly €35 for the approved material, a saving near 90 percent on the single most scrutinised input in the product. On that margin Mas built the world's third-largest implant business, shipping an estimated two million implant sets over two decades to clinics across some 65 countries. The wonder was never the engineering; it was the discount — and the discount existed only because the substitution was concealed from everyone the system relied on to catch it.
Thirteen Inspections and Two Sets of Books
The defect was not subtle chemistry but documented deceit. PIP allegedly maintained parallel records — one reality for the auditors, another on the factory floor — and, by Mas's own admission to investigators, had employees remove the industrial gel before TÜV Rheinland's annual inspections. The German certifier, whose mark let PIP sell across the European Economic Area, audited the firm repeatedly between the late 1990s and 2010 and signed off each time, never sampling the gel in a way that would have exposed the swap. The failure mode was structural: the European conformity system trusted manufacturer-supplied documentation and announced, scheduled audits — a regime a determined fraudster could route around. The signal was not buried in obscure data; it was the product itself, sitting in tens of thousands of women and rupturing at five times the expected rate. It took a French regulator's on-site inspection in 2010, not the standing certification chain, to find what more than a decade of audits had missed.
Liquidation, a Prison Cell, and a Liable Certifier
The reckoning arrived in stages, and the device was withdrawn long before any of it resolved. AFSSAPS suspended the implants and exposed the unapproved silicone in March 2010; PIP collapsed into liquidation almost immediately, owing on the order of €9 million. Recall scattered into a patchwork of national responses — France's December 2011 advice to remove some 30,000 implants stood at the aggressive end. Criminal liability landed on Mas: convicted of aggravated fraud in Marseille on 10 December 2013, sentenced to four years and €75,000, the conviction confirmed at Aix-en-Provence in May 2016. The most consequential judgment fell on the gatekeeper. After years of conflicting rulings, the Paris Court of Appeal held on 20 May 2021 that TÜV Rheinland had negligently certified PIP and was liable to victims, ordering interim payments of €3,000 per claimant. The bodies, the bankruptcy, and the certifier's negligence — not any pre-market safeguard — wrote the ending.
Contributing Factors
Aftermath
PIP's most durable consequence was regulatory: its exposure became the textbook case for overhauling Europe's medical-device framework, culminating in EU Regulation 2017/745, the Medical Device Regulation, which tightened notified-body oversight and mandated unannounced audits of manufacturers and critical subcontractors — the precise gap PIP had exploited. The financial reckoning ran through the courts for more than a decade: Mas served part of his four-year sentence and was released in 2016, while litigation against TÜV Rheinland produced the landmark May 2021 Paris ruling holding the certifier liable, with interim damages ordered for hundreds of claimants. The human residue was hardest to close — hundreds of thousands of women left to decide whether to surgically remove a device sold to them as safe, many of them breast-cancer survivors who had already endured one operation. Today PIP is the byword for material-substitution fraud and notified-body failure: the case invoked whenever a CE mark is mistaken for proof a manufacturer used what its certificate claims.
Lessons
- Test the material, not the paperwork: a certification regime that audits documents and announces its visits can be defeated by anyone willing to keep two sets of books, so independent sampling and unannounced inspection are the only checks a determined substitutor cannot route around.
- Treat an implausibly low price as a safety signal — when a CE-marked device undercuts the field by a wide margin, ask where the saving came from, because the cheapest input is usually the one most worth faking.
- Distinguish recall from retrieval: pulling a product and bankrupting its maker leaves the hazard inside every patient already implanted, so plan for in-body removal and cross-border follow-up, not just suspension of sales.
- Map liability before you need it — when the primary wrongdoer can go bankrupt and its founder is judgment-proof, victims' only recourse is the gatekeeper who signed off, so hold certifiers to a standard that assumes the manufacturer may be lying.
- Read a single notorious failure as the draft of the next law: PIP wrote the MDR, so operate as though the safeguard your fraud reveals will become mandatory the moment it is exposed.